Natasa Rajicic
- Hepatology top 1%
- Virology top 2%
- HIV Research and Treatment 6
- Infectious Diseases top 5%
- HIV/AIDS drug development and treatment 4
- HIV/AIDS Research and Interventions 4
- Emergency Medicine top 5%
- HIV-related health complications and treatments 4
- Epidemiology top 5%
-
- Growth Hormone and Insulin-like Growth Factors 5
- Pituitary Gland Disorders and Treatments 4
-
- Lipid metabolism and disorders 3
-
- Statistical Methods in Clinical Trials 3
- Co-authors
- Kenneth E. ShermanSusan D. RousterRaymond T. ChungJames GoodrichNorah J. ShireJayvant HeeraEzio GhigoHoward Mayer
- Partner nations
- United StatesUnited KingdomItaly
In The Last Decade
Natasa Rajicic
31 papers receiving 1.6k citations
Hit Papers
Peers
Comparison fields: 5 of 103
- Hepatology 632
- Virology 293
- Infectious Diseases 496
- Emergency Medicine 215
- Epidemiology 715
Countries citing papers authored by Natasa Rajicic
This map shows the geographic impact of Natasa Rajicic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natasa Rajicic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natasa Rajicic more than expected).
Fields of papers citing papers by Natasa Rajicic
This network shows the impact of papers produced by Natasa Rajicic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natasa Rajicic. The network helps show where Natasa Rajicic may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Natasa Rajicic, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 14 | |
| 2 | 2020 | 34 | |
| 3 | 2015 | 6 | |
| 4 | 2013 | 6 | |
| 5 | 2012 | 168 | |
| 6 | 2012 | 9 | |
| 7 | Long-term treatment of acromegaly with pegvisomant (Somavert): cross-sectional observations from ACROSTUDY, a post-marketing, international, safety, surveillance study | 2011 | 0 |
| 8 | 2011 | 42 | |
| 9 | 2010 | 12 | |
| 10 | 2010 | 61 | |
| 11 | 2010 | 39 | |
| 12 | 2009 | 54 | |
| 13 | 2008 | 33 | |
| 14 | 2008 | 53 | |
| 15 | 2006 | 7 | |
| 16 | 2005 | 23 | |
| 17 | 2002 | 143 | |
| 18 | 2002 | 68 | |
| 19 | Hepatitis C Virus Prevalence among Patients Infected with Human Immunodeficiency Virus: A Cross-Sectional Analysis of the US Adult AIDS Clinical Trials Groupbreakdown → | 2002 | 586 |
| 20 | 2000 | 19 |
About Natasa Rajicic
Natasa Rajicic is a scholar working on Virology, Infectious Diseases and Emergency Medicine, having authored 33 papers that have together received 1.7k indexed citations. Recurring topics across this work include HIV Research and Treatment (6 papers), Growth Hormone and Insulin-like Growth Factors (5 papers), Pituitary Gland Disorders and Treatments (4 papers), HIV-related health complications and treatments (4 papers), HIV/AIDS drug development and treatment (4 papers), HIV/AIDS Research and Interventions (4 papers), Lipid metabolism and disorders (3 papers) and Statistical Methods in Clinical Trials (3 papers). The work is most often cited by research in Hepatology (632 citations), Virology (293 citations) and Infectious Diseases (496 citations). Natasa Rajicic has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Kenneth E. Sherman, Susan D. Rouster, Raymond T. Chung, James Goodrich, Norah J. Shire, Jayvant Heera, Ezio Ghigo, Howard Mayer, Beverly M. K. Biller and Judith Hey‐Hadavi. Their work appears in journals such as Circulation, Journal of Clinical Oncology and Bioinformatics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.